|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,835.10 INR | +0.56% |
|
+1.52% | +6.72% |
| 06-10 | Organon wins US approval to widen use of arthritis biosimilar drug | RE |
| 06-09 | Organon Acquisition May Receive $1 Billion Commitment From State Bank of India | MT |
| Market Cap | 4,378B 46.46B 40.48B 37.31B 35.1B 65.66B 66.12B 444B 172B 2,158B 174B 171B 7,479B | P/E 2026 |
36.8x | P/E 2027 * | 33.3x |
|---|---|---|---|---|---|
| Enterprise Value | 4,154B 44.08B 38.4B 35.4B 33.3B 62.3B 62.73B 421B 164B 2,047B 165B 162B 7,096B | EV / Sales 2026 |
6.72x | EV / Sales 2027 * | 6.29x |
| Free-Float |
44.39% | Yield 2026 |
0.91% | Yield 2027 * | 0.87% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.57% | ||
| 1 week | +1.52% | ||
| Current month | +2.00% | ||
| 1 month | -2.50% | ||
| 3 months | +5.21% | ||
| 6 months | +5.18% | ||
| Current year | +6.72% |
| 1 week | 1,792.6 |  | 1,839.1 |
| 1 month | 1,756.8 | | 1,903 |
| Current year | 1,583.7 | | 1,916.6 |
| 1 year | 1,548 | | 1,916.6 |
| 3 years | 977.3 | | 1,960.35 |
| 5 years | 661.5 | | 1,960.35 |
| 10 years | 312 | | 1,960.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 2025-08-31 | |
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | 58 | 2025-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 73 | 2018-05-24 | |
| Director/Board Member | 70 | 2021-05-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.56% | +1.52% | +11.39% | +83.19% | 46.46B | |
| -2.91% | +3.09% | +49.98% | +91.04% | 35.42B | |
| -0.05% | -2.48% | -8.70% | +33.98% | 11.62B | |
| -0.25% | -3.02% | +12.76% | +93.32% | 11.47B | |
| +1.33% | +2.14% | +38.16% | +129.26% | 9.13B | |
| +0.77% | -1.34% | +14.61% | +40.96% | 6.94B | |
| -1.23% | +1.65% | +43.80% | -18.26% | 6.65B | |
| +1.56% | +0.67% | +33.50% | +241.72% | 6.45B | |
| +0.73% | -2.44% | -37.77% | -7.15% | 5.01B | |
| -4.88% | 0.00% | +63.86% | +356.60% | 4.01B | |
| Average | -0.47% | +0.39% | +22.16% | +104.47% | 14.31B | |
| Weighted average by Cap. | -0.55% | +1.73% | +23.53% | +89.77% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 583B 6.18B 5.39B 4.96B 4.67B 8.74B 8.8B 59.07B 22.94B 287B 23.2B 22.7B 995B | 654B 6.94B 6.05B 5.58B 5.24B 9.81B 9.88B 66.34B 25.76B 322B 26.06B 25.5B 1,118B |
| Net income | 116B 1.23B 1.07B 988M 929M 1.74B 1.75B 11.75B 4.56B 57.12B 4.62B 4.52B 198B | 133B 1.41B 1.23B 1.13B 1.06B 1.99B 2B 13.44B 5.22B 65.34B 5.28B 5.17B 226B |
| Net Debt | -224B -2.38B -2.07B -1.91B -1.8B -3.36B -3.39B -22.74B -8.83B -111B -8.93B -8.74B -383B | -264B -2.8B -2.44B -2.25B -2.11B -3.96B -3.98B -26.75B -10.39B -130B -10.51B -10.28B -451B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-19 | 1,835.10 ₹ | +0.56% | 821,948 |
| 26-06-18 | 1,824.80 ₹ | +0.24% | 2,054,738 |
| 26-06-17 | 1,820.40 ₹ | +1.09% | 1,771,990 |
| 26-06-16 | 1,800.70 ₹ | -0.29% | 1,373,638 |
| 26-06-15 | 1,806.00 ₹ | -0.09% | 2,188,933 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
